| Product NDC: | 0173-0570 |
| Proprietary Name: | ZOFRAN |
| Non Proprietary Name: | ondansetron hydrochloride |
| Active Ingredient(s): | 8 mg/1 & nbsp; ondansetron hydrochloride |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, ORALLY DISINTEGRATING |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0173-0570 |
| Labeler Name: | GlaxoSmithKline LLC |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020781 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19990301 |
| Package NDC: | 0173-0570-00 |
| Package Description: | 30 TABLET, ORALLY DISINTEGRATING in 1 DOSE PACK (0173-0570-00) |
| NDC Code | 0173-0570-00 |
| Proprietary Name | ZOFRAN |
| Package Description | 30 TABLET, ORALLY DISINTEGRATING in 1 DOSE PACK (0173-0570-00) |
| Product NDC | 0173-0570 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | ondansetron hydrochloride |
| Dosage Form Name | TABLET, ORALLY DISINTEGRATING |
| Route Name | ORAL |
| Start Marketing Date | 19990301 |
| Marketing Category Name | NDA |
| Labeler Name | GlaxoSmithKline LLC |
| Substance Name | ONDANSETRON |
| Strength Number | 8 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Serotonin 3 Receptor Antagonists [MoA],Serotonin-3 Receptor Antagonist [EPC] |